When HbA1c Misleads: Reading the Test's Blind Spots

HbA1c estimates average glucose by measuring the fraction of hemoglobin that has been glycated, and it quietly assumes a normal red blood cell lifespan and normal hemoglobin. When those assumptions break, from anemia, hemoglobin variants, kidney disease, or fast red cell turnover, the number can drift away from true glycemia. The practical signal is discordance: when HbA1c and day to day glucose readings disagree, the test, not the patient, may be the problem.

What the number actually measures

HbA1c reports the percentage of hemoglobin molecules that have picked up glucose through a slow, nonenzymatic reaction. Because red blood cells circulate for about four months, the test reflects average blood sugar over roughly the preceding two to three months, weighted toward the most recent weeks.

That elegance hides an assumption. The result depends not only on how much glucose is in the blood but on how long red cells hang around to be glycated and on the hemoglobin they carry. Change the cells or the hemoglobin, and the same average glucose can produce a different HbA1c.

When faster or slower red cell turnover shifts the result

If red cells are cleared early, they spend less time bathing in glucose, so HbA1c can read falsely low. This happens in hemolytic anemia, after recent blood loss, during recovery from anemia, in the later stages of pregnancy, and with treatments that spur new red cell production.

The mirror image raises the number. When red cells survive longer than usual, or when new cell production is sluggish, a larger fraction of old, heavily glycated cells remains in circulation. According to the NGSP, iron deficiency anemia tends to elevate HbA1c, and the level falls again once iron is replaced. The lesson is that the test tracks red cell life history as much as sugar.

Hemoglobin variants and the method that reads them

Inherited hemoglobin variants such as HbS, HbC, HbE, and HbD traits, along with elevated fetal hemoglobin, can interfere with measurement. Whether the interference pushes the value up or down, and by how much, depends on the specific variant and on the analytical method the laboratory uses.

This is why two laboratories can disagree on the same sample. Multicentre evaluations of standardized analyzers show that some methods are unaffected by common variants while others carry a clinically meaningful bias. When a result looks implausible in someone with a known trait, the reasonable question is not just what the value is but which assay produced it.

Kidney disease and the harder cases

Chronic kidney disease stacks several confounders at once. Shortened red cell survival, anemia, treatment that stimulates red cell production, and chemically modified hemoglobin can all nudge HbA1c away from true glycemia, often toward underestimation.

In settings like advanced kidney disease, clinicians may lean on alternative markers such as glycated albumin or fructosamine, or on direct glucose data, rather than trusting HbA1c alone. The point for a careful reader is that HbA1c is least reliable exactly where the stakes for glucose control can be high.

Reading discordance instead of a single value

The most practical safeguard is comparison. Continuous glucose monitoring produces a Glucose Management Indicator, an estimate of HbA1c derived from measured glucose, described in the international consensus on time in range. When laboratory HbA1c and this glucose derived estimate agree, confidence rises. When they diverge sharply, that gap is a clue that a red cell or hemoglobin factor is distorting the test.

None of this makes HbA1c a bad test. It is a well standardized, population calibrated estimate that serves most people well. It simply is not a truth serum, and the skill is knowing the handful of situations where the number deserves a second look rather than an automatic response.